|
Bellerophon Therapeutics inc (NASDAQ: BLPH) |
|
Bellerophon Therapeutics inc
BLPH's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Bellerophon Therapeutics Inc's sales fell
in III. Quarter 2023 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -4.76 %
Bellerophon Therapeutics Inc net loss decreased from $-5 millions, to $-2 millions in III. Quarter 2023,
• More on BLPH's Growth
|
|
Bellerophon Therapeutics Inc realized a net loss in trailing twelve months.
Bellerophon Therapeutics Inc realized cash reduction of $ -0.23 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 0.03.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.4.
• More on BLPH's Valuation
|
|
|
|
|
Bellerophon Therapeutics Inc realized net loss in trailing twelve months.
Bellerophon Therapeutics Inc realized cash outflow of $ -0.23per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 0.03.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.4.
Bellerophon Therapeutics Inc Price to Book Ratio is at 0.04 lower than Industry Avg. of 87.76. and higher than S&P 500 Avg. of 0.02
• More on BLPH's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com